Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris

被引:146
|
作者
Chams-Davatchi, Cheyda
Esmaili, Nafiseh
Daneshpazhooh, Maryam
Valikhani, Mahin
Balighi, Kamran
Hallaji, Zahra
Barzegari, Masoumeh
Akhyani, Maryam
Ghodsi, S. Zahra
Seirafi, Hassan
Tabrizi, Mohammad-Javad Nazemi
Mortazavi, Hossein
Mirshams-Shahshahani, Mostafa
机构
[1] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Tehran 11996, Iran
[2] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Pemphigus Res Unit, Tehran, Iran
关键词
D O I
10.1016/j.jaad.2007.05.024
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Pemphigus is a severe autoimmune blistering disease affecting the skin and mucosa. Mortality is high in the absence of treatment. Nowadays, treatment is based mainly on corticosteroids and cytotoxic drugs; however, because of the rarity of the disease worldwide, there is not yet a standard treatment based on randomized controlled trials, and the treatment used is based mainly on the experience of experts. Objective: The aim of this study was to compare the efficacy and safety of 4 treatment regimens for pemphigus vulgaris: prednisolone alone, prednisolone plus azathioprine, prednisolone plus mycophenolate mofetil, and prednisolone plus intravenous cyclophosphamide pulse therapy. Methods: One hundred twenty new cases of pemphigus vulgaris were enrolled. These patients were randomly allocated into 1 of 4 treatment groups (each comprising 30 patients) and received prednisolone (P), prednisolone and azathioprine (P/A), prednisolone and mycophenolate mofetil (P/MM), and prednisolone and intravenous cyclophosphamide pulse therapy (P/PC). They were followed up for I year at the Pemphigus Research Unit. Results: In groups P, P/A, P/MM, and P/PC, 23 (76.5%), 24 (80%), 21 (70%), and 22 (73.3%) of the patients, respectively, followed the regimen for the full 1-year period. The mean total dose of prednisolone administered in groups P, P/A, P/MM, and P/PC was 11631 mg (standard deviation [SD] = 7742), 7712 mg (SD = 955), 9798 mg (SD = 3995), and 8276 mg (SD = 810), respectively. The mean total dose of prednisolone in group P (prednisolone alone) was 11,631 mg, The mean total dose of prednisolone in the 3 cytotoxic groups was 8652 mg. By using analysis of variance, the difference was statistically significant (P =.047). in the cytotoxic groups, there was a significant difference between the P/A and P/MM groups (P =.007), but not between P/A and P/PC (P =.971), and P/MM and P/PC (P =.670). Side effects were not significantly different among the 4 groups. Limitations: Larger sample sizes and blind design are suggested for future studies. Conclusion. The efficacy of prednisolone is enhanced when it is combined with a cytotoxic drug. The most efficacious cytotoxic drug to reduce steroid was found to be azathioprine, followed by cyclophosphamide (pulse therapy), and mycoplienolate mofetil.
引用
收藏
页码:622 / 628
页数:7
相关论文
共 50 条
  • [21] Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial
    Goebeler, M.
    Bata-Csorgo, Z.
    De Simone, C.
    Didona, B.
    Remenyik, E.
    Reznichenko, N.
    Stoevesandt, J.
    Ward, E. S.
    Parys, W.
    de Haard, H.
    Dupuy, P.
    Verheesen, P.
    Schmidt, E.
    Joly, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 429 - 439
  • [22] An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD
    Ni, Hsing-Chang
    Lin, Yu-Ju
    Gau, Susan Shur-Fen
    Huang, Hui-Chun
    Yang, Li-Kuang
    JOURNAL OF ATTENTION DISORDERS, 2017, 21 (01) : 27 - 39
  • [23] Acupuncture in migraine prophylaxis in Czech patients: an open-label randomized controlled trial
    Musil, Frantisek
    Pokladnikova, Jitka
    Pavelek, Zbysek
    Wang, Bo
    Guan, Xin
    Valis, Martin
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 1221 - 1228
  • [24] Open-Label Placebo Treatment for Cancer-Related Fatigue: A Randomized-Controlled Clinical Trial
    Teri W. Hoenemeyer
    Ted J. Kaptchuk
    Tapan S. Mehta
    Kevin R. Fontaine
    Scientific Reports, 8
  • [25] Foley Catheter for Induction of Labor at Term: An Open-Label, Randomized Controlled Trial
    Gu, Ning
    Ru, Tong
    Wang, Zhiqun
    Dai, Yimin
    Zheng, Mingming
    Xu, Biyun
    Hu, Yali
    PLOS ONE, 2015, 10 (08):
  • [26] Almond oil for patients with hyperlipidemia: A randomized open-label controlled clinical trial
    Zibaeenezhad, Mohammad Javad
    Ostovan, Parham
    Mosavat, Seyed Hamdollah
    Zamirian, Mahmood
    Attar, Armin
    COMPLEMENTARY THERAPIES IN MEDICINE, 2019, 42 : 33 - 36
  • [27] Relapse in psoriasis with two different tapering regimens of methotrexate: A randomized open-label controlled study
    Singh, Satyendra Kumar
    Rai, Tulika
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2015, 81 (02): : 144 - 147
  • [28] Efficacy of RestoreX after prostatectomy: open-label phase of a randomized controlled trial
    Zganjar, Andrew
    Toussi, Amir
    Ziegelmann, Matthew
    Frank, Igor
    Boorjian, Stephen A. A.
    Tollefson, Matthew
    Kohler, Tobias
    Trost, Landon
    BJU INTERNATIONAL, 2023, 132 (02) : 217 - 226
  • [29] Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial
    Schaefer, Michael
    Harke, Rebecca
    Denke, Claudia
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2016, 85 (06) : 373 - 374
  • [30] Comparison of Prednisolone, Etoricoxib, and Indomethacin in Treatment of Acute Gouty Arthritis: An Open-Label, Randomized, Controlled Trial
    Xu, Lingling
    Liu, Shiqun
    Guan, Meiping
    Xue, Yaoming
    MEDICAL SCIENCE MONITOR, 2016, 22 : 810 - 817